相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease
Gary W. Zlotnick et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males
Chyongchiou Jeng Lin et al.
VACCINE (2014)
A Randomized, Controlled, Phase 1/2 Trial of a Neisseria meningitidis Serogroup B Bivalent rLP2086 Vaccine in Healthy Children and Adolescents
Michael D. Nissen et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2013)
A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults
Helen S. Marshall et al.
VACCINE (2013)
Global epidemiology of invasive meningococcal disease
Rabab Z. Jafri et al.
POPULATION HEALTH METRICS (2013)
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial
Peter C. Richmond et al.
LANCET INFECTIOUS DISEASES (2012)
A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase-1 trial
P. C. Richmond et al.
VACCINE (2012)
A Phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults
Eric A. Sheldon et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Characterization of Neisseria meningitidis Isolates That Do Not Express the Virulence Factor and Vaccine Antigen Factor H Binding Protein
Jay Lucidarme et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Randomized Trial of an Alternate Human Papillomavirus Vaccine Administration Schedule in College-Aged Women
Richard K. Zimmerman et al.
JOURNAL OF WOMENS HEALTH (2010)
Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
Han-Qing Jiang et al.
VACCINE (2010)
Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup B Neisseria meningitidis
Ellen Murphy et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease
Carl E. Frasch et al.
VACCINE (2009)
Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide
Lisa K. McNeil et al.
VACCINE (2009)
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance
Guillermo Madico et al.
JOURNAL OF IMMUNOLOGY (2006)
The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB
DR Martin et al.
CLINICAL AND VACCINE IMMUNOLOGY (2006)
Meningococcal surrogates of protection - serum bactericidal antibody activity
R Borrow et al.
VACCINE (2005)
The concept of tailor-made, protein-based, outer membrane vesicle vaccines against meningococcal disease
J Holst et al.
VACCINE (2005)
Vaccine potential of the Neisseria meningitidis 2086 lipoprotein
LD Fletcher et al.
INFECTION AND IMMUNITY (2004)